NCT06660524
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
StatusUnknown
PhasePhase 4
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
The change of valve calcification score on CT scan from baseline to 1 year of treatment.
Timeframe: from baseline to 1 year of treatment
Secondary (1)
major cardiovascular events
Arms and interventions
Sevelamer TreatmentExperimental
Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Calcium Carbonate TreatmentActive comparator
Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Drugs: Sevelamer, Calcium carbonate
Sites
1 site in 1 country
- Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical ScienceBeijing, Beijing Municipality, China